Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
AA

Ratings ESG MSCI

Ratings Chugai Pharmaceutical Co., Ltd.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company has a good ESG score relative to its sector, according to MSCI.
Highlights: Chugai Pharmaceutical Co., Ltd.
  • The company's profit outlook over the next few years is a strong asset.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Sales forecast by analysts have been recently revised upwards.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: Chugai Pharmaceutical Co., Ltd.
  • With a 2025 P/E ratio at 37.51 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • The company is highly valued given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Rating Financials

Chugai Pharmaceutical Co., Ltd. SectorJapan

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Chugai Pharmaceutical Co., Ltd. SectorJapan

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Chugai Pharmaceutical Co., Ltd. SectorJapan

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Chugai Pharmaceutical Co., Ltd. SectorJapan

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Chugai Pharmaceutical Co., Ltd. SectorJapan

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
102B
AA
897B
A
591B
BBB
418B
AA
368B
AA
313B
A
312B
AAA
297B
A
204B
A
184B
AAA
Average 368.6B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Equities
  3. 4519 Stock
  4. Ratings Chugai Pharmaceutical Co., Ltd.